These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37568417)

  • 1. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
    Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
    Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
    Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease.
    Choden T; Cohen NA; Rubin DT
    Gastroenterol Hepatol (N Y); 2022 May; 18(5):265-271. PubMed ID: 36397756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.
    Rowan C; Ungaro R; Mehandru S; Colombel JF
    Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
    Aoun R; Hanauer S
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 7. Etrasimod for the treatment of ulcerative colitis.
    Wils P; Peyrin-Biroulet L
    Immunotherapy; 2023 Apr; 15(5):311-321. PubMed ID: 36789612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on ozanimod for ulcerative colitis.
    Antonelli EK; Del Sordo R; Morelli O; Villanacci V; Bassotti G
    Drugs Today (Barc); 2022 Jul; 58(7):351-367. PubMed ID: 35851870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
    Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
    Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease.
    Verstockt B; Vetrano S; Salas A; Nayeri S; Duijvestein M; Vande Casteele N;
    Nat Rev Gastroenterol Hepatol; 2022 Jun; 19(6):351-366. PubMed ID: 35165437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.
    Massironi S; Furfaro F; Bencardino S; Allocca M; Danese S
    J Gastroenterol; 2024 Sep; 59(9):761-787. PubMed ID: 38980426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ozanimod: A Review in Ulcerative Colitis.
    Paik J
    Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
    Al-Shamma H; Lehmann-Bruinsma K; Carroll C; Solomon M; Komori HK; Peyrin-Biroulet L; Adams J
    J Pharmacol Exp Ther; 2019 Jun; 369(3):311-317. PubMed ID: 30872391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.
    Wang J; Goren I; Yang B; Lin S; Li J; Elias M; Fiocchi C; Rieder F
    Aliment Pharmacol Ther; 2022 Feb; 55(3):277-291. PubMed ID: 34932238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine.
    Dal Buono A; Gabbiadini R; Alfarone L; Solitano V; Repici A; Vetrano S; Spinelli A; Armuzzi A
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.